This study investigated correlations between mortality, stroke subtype and stroke severity with serum osteoprotegerin (OPG) and S-100 protein levels prior to the treatment of patients admitted to the emergency department and diagnosed with ischaemic stroke. Pretreatment serum samples were collected from patients (n = 90) to determine OPG and S-100 protein levels. Age-and sex-matched healthy individuals (n = 16) served as controls. Compared with controls, OPG and S-100 protein levels were significantly higher in the cardioembolic and atherothrombotic stroke groups. Within the stroke group, OPG levels were significantly higher in the cardioembolic and atherothrombotic stroke groups compared with the transient ischaemic attack (TIA) group. S-100 protein levels were significantly higher in the atherothrombotic stroke group than in the lacunar stroke and TIA groups, and in the cardioembolic stroke group compared with the lacunar stroke group. Serum OPG and S-100 protein levels were significantly higher in patients who died compared with survivors. In predicting stroke subtype and severity, although both OPG and S-100 protein levels were indicators, S-100 protein was more valuable for mortality prediction. KEY WORDS: ISCHAEMIC STROKE; MORTALITY; STROKE SEVERITY; OSTEOPROTEGERIN; S-100 PROTEIN M Üstündag, M Orak, C Güloglu et al. Serum OPG and S-100 protein in acute ischaemic stroke
Introduction
Neurobiochemical markers have gained special importance in the determination of brain damage resulting from ischaemic stroke. In ischaemic stroke, many biochemical and immunological reactions take place secondary to the declining cerebral blood flow. Measurement of blood levels of various proteins and other substances has been used to determine brain damage after cerebral hypoxia and ischaemia. 1 Determination of these substances makes it possible to reach a faster diagnosis and to start treatment earlier.
Although it is possible for these kinds of biochemical markers to show the severity of cerebral damage, the amount of information they give about the anatomical localization and clinical importance of injury is still debatable. 2 M Üstündag, M Orak, C Güloglu et al. Serum OPG and S-100 protein in acute ischaemic stroke Elevated S-100 protein levels in cerebrospinal fluid in situations of acute cerebral damage, such as ischaemic stroke, cerebral bleeding, cerebral hypoxia and head trauma, have been reported previously. 3 -5 The difficulty of collecting cerebrospinal fluid samples by the lumbar puncture method is directing researchers to examine biochemical markers in the blood. Osteoprotegerin (OPG) is a cytokine secreted by the vascular endothelial and smooth muscle cells. 6 Previous studies have shown a relationship between OPG levels and the severity of coronary arteriosclerosis. 7 -9 On the basis of these data, OPG may play an important role in the development of vascular diseases. To our knowledge, only one study has investigated the relationship between OPG and ischaemic stroke and, in that study, only the correlation between stroke subtype and OPG level was researched. 10 To our knowledge, no study in the literature has examined the relationship in stroke patients between OPG and S-100 protein levels and mortality, stroke subtype and stroke severity. For this reason, the correlations between OPG and S-100 protein levels, measured before specific treatment was given, and mortality, stroke subtype and stroke severity were examined in patients with ischaemic stroke admitted to a hospital emergency department. who were admitted to the department because of headache, osteoarthritis or minor trauma, were recruited into the study as a control group. Inclusion criteria for the study were acute ischaemic stroke and consent to be included in the study. Exclusion criteria were: acute haemorrhagic stroke; peripheral vascular disease; systemic inflammatory disorder or tumour; treatment that could affect inflammatory responses (hormonal replacement therapy, non-steroidal antiinflammatory drugs, corticosteroids, etc.); patients who could not be classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria and whose National Institutes of Health Stroke Scale (NIHSS) score could not be calculated at the time of admission. 11, 12 The study was conducted with the consent of the Ethical Committee Presidency of Dicle University Faculty of Medicine. The patients, or their relatives, and the healthy volunteers provided written consent to participate in the study.
Patients and methods PATIENTS

STROKE CLASSIFICATION
Cerebral computed tomography (CT) (Activion 16 Multislice CT System; Toshiba, Tokyo, Japan) or magnetic resonance imaging (MRI) (Achieva 1.5T A-series MRI; Philips Healthcare, Best, The Netherlands) scanning was carried out on all patients in order to eliminate haemorrhagic stroke or other intracerebral diseases, and to classify the stroke subtype. 8, 9 According to the standard treatment algorithm, patients were treated in accordance with their diagnosis. Subextremity Doppler was applied to all patients to diagnose deep venous thrombosis and venous thromboembolism, along with echocardiography (Vivid S6; GE Healthcare Biosciences, Piscataway, NJ, USA), abdominal ultrasonography and carotid ultrasonography (SSA-790A Aplio™ XG V1-Serum OPG and S-100 protein in acute ischaemic stroke 10, Toshiba) . Medical, demographic, clinical, laboratory and radiological records of all patients were examined. Radiological findings of cerebral ischaemia were recorded according to the vein map of Tatu et al. 13 Stroke subtypes, classified according to the TOAST criteria, and stroke severity, classified according to NIHSS scores, were determined in all patients by a single neurologist. 11, 12 Patients were then classified into four stroke severity subgroups according to their NIHSS scores on admission: NIHSS 0, normal; NIHSS 1 -7, low severity; NIHSS 8 -14, moderate severity; and NIHSS ≥ 15, high severity. 14
OPG AND S-100 PROTEIN MEASUREMENTS
Blood samples were collected from all patients prior to specific treatment being given. On admission, venous samples were collected from an antecubital vein without using a tourniquet. Samples were centrifuged within 15 min of collection at 3000 g for 10 min and the supernatant serum samples were transferred into polypropylene tubes and stored at −80°C until assays were carried out. Researchers carried out a blinded determination of OPG and S-100 protein levels in serum collected from both patients and control subjects. OPG levels were measured using a commercially available enzyme-linked immunosorbent assay kit (BioVendor Laboratory Medicine, Brno, Czech
Republic) according to the manufacturer's instructions. S-100 protein concentrations were determined using an electro-chemiluminescent immunoassay method (Modular Analytics E170; Roche Diagnostics Corp., Indianapolis, IN, USA).
STATISTICAL ANALYSES
Results are given as mean ± SD. Statistical analyses were carried out using the SPSS ® statistical package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . Univariate statistical analysis was performed for the categorical variables using the χ 2 -test, and Fisher's exact test and Student's t-test for the continuous variables. For the within-group comparisons, Kruskal-Wallis one-way analysis of variance was used, and the Mann-Whitney U-test was used as a multiple comparison method; this was because the groups showed a non-normal distribution and the number of subjects in each group was not equal. For the within-group comparisons, P-values < 0.01 were considered to be statistically significant and for other comparisons, P-values < 0.05 were considered to be statistically significant.
Stepwise backward Wald logistic regression analysis was used in the multivariate analysis for variables that were found to be significant in the univariate analyses carried out to determine the independent predictors of mortality.
Results
PATIENTS
The study included 90 consecutive patients with a definite diagnosis of ischaemic stroke: 35 (38.9%) males and 55 (61.1%) females. In addition, 16 healthy volunteers (seven [43.8%] males and nine [56.3%] females), similar to the patient cohort in terms of age and sex, formed the control group. The mean ± SD age of the patients was 65.1 ± 10.0 years and of the controls was 63.5 ± 3.1. The mean ± SD admission time of patients was 7.3 ± 5.2 h and the mean ± SD length of hospital stay was 10.2 ± 7.6 days. Clinical characteristics of the patients are shown in Table 1 .
STROKE CATEGORY AND SERUM OPG AND S-100 PROTEIN LEVELS
Serum S-100 protein concentrations were Serum OPG and S-100 protein in acute ischaemic stroke increased above the normal value (0.02 ± 0.08 µg/l) in 83 (92.2%) patients with stroke (odds ratio [OR] 15.24; 95% CI 4.35, 53.38; Fisher's exact test, P < 0.001). Serum OPG levels were raised above the normal range (5.6 -7.2 pmol/l) in 75 (83.3%) patients with stroke (OR 6.43; 95% CI 2.07, 19.95; Fisher's exact test, P = 0.0015). Serum OPG and S-100 protein levels showed variability in accordance with the different stroke types (Figs 1 and 2 ). According to the TOAST criteria, 12 compared with the control group, patients with cardioembolic stroke and atherothrombotic stroke had significantly higher levels of serum OPG and S-100 protein (all comparisons P < 0.001) ( Table 2 ). There were no significant differences in levels of serum OPG and S-100 protein between the control group and patients in the transient ischaemic attack (TIA) and lacunar stroke groups.
When within-patient group comparisons were made, there was a statistically significant difference in serum OPG (P < 0.001) and S-100 protein (P < 0.001) levels between the groups according to stroke subtype ( Table 2 ). Serum OPG levels were significantly higher in the cardioembolic stroke and atherothrombotic stroke groups than in the TIA group (both comparisons P < 0.001). Serum S-100 protein levels were significantly higher in the atherothrombotic stroke group compared with the lacunar stroke and TIA groups (P < 0.001 and P = 0.006, respectively). Serum S-100 protein levels were also significantly higher in the cardioembolic stroke group compared with the lacunar stroke group (P < 0.001).
STROKE SEVERITY AND SERUM OPG AND S-100 PROTEIN LEVELS
According to the NIHSS score for stroke severity, 11 compared with the control group, patients with low severity, moderate severity and high severity strokes had significantly higher serum OPG levels (P = 0.001, P = 0.006 and P < 0.001, respectively) and S-100 protein levels (all comparisons P < 0.001) ( Table 2 ). When within-patient group comparisons were made for stroke severity, there was a statistically significant difference for both the serum OPG (P = 0.005) and S-100 protein (P = 0.007) levels. Serum OPG levels were significantly higher in patients with high severity stroke compared with Serum OPG and S-100 protein in acute ischaemic stroke those who had low and moderately severe strokes (P = 0.003 and P = 0.006, respectively). In contrast, serum S-100 protein levels were significantly higher in the patients with high severity stroke when compared with the patients with strokes of low severity (P = 0.001).
MORTALITY AND SERUM OPG AND S-100 PROTEIN LEVELS
In total, 28 (31.1%) patients died during the study. While there was no significant difference between the patients who died and those who survived with regard to gender, there was a significant difference in age (P = 0.013). Demographic and clinical differences between the patients who died and those who survived are given in Table 3 . Mortality was significantly higher in the patients who had a left atrial thrombus (P = 0.002), indentified using transthoracic echocardiography, and in patients with a cardioembolic stroke (P = 0.002), classified using the TOAST criteria. 12 OPG and S-100 protein levels were significantly higher in patients who died compared with those who survived (P = 0.001 and P = 0.003, respectively). Of the 28 patients who died, 20 (71.4%) had NIHSS scores ≥ 15 (P < 0.001). When the variables that were found to have affected mortality were evaluated in a univariate analysis using the logistic regression method, the following were effective independent predictors of mortality: existence of a left atrial thrombus (OR 0.120; 95% CI 0.023, 0.625; P = 0.012); serum S-100 protein level (OR 19.740; 95% CI 2.614, 149.04; P = 0.004); and an NIHSS score of ≥ 15 (OR 39.743; 95% CI 8.704, 181.47; P < 0.001) ( Table 4 ). 
Discussion
Primarily, the present study confirmed that serum OPG and S-100 protein levels are higher in patients with ischaemic stroke, compared with healthy individuals.
Clinical studies have shown that high serum OPG levels are an independent risk factor for progressive atherosclerosis and cardiovascular diseases. 15 -17 In the literature, several studies have investigated OPG levels in acute ischaemic stroke, but studies on the role of OPG in ischaemic stroke are still insufficient. Guldiken et al. 10 studied serum OPG levels in 51 patients with acute ischaemic stroke and reported that OPG levels were higher in an atherothrombotic stroke group with large vessel disease than in a lacunar stroke group with small vessel disease. Browner et al. 18 showed the existence of high OPG levels and reported a relationship between OPG levels and fatal stroke risk in a study of postmenopausal women over the age of 65 years who died of stroke or other vascular disease. The present study demonstrated that serum OPG levels, determined before specific treatment is given in patients with ischaemic stroke, may be a useful marker in predicting stroke subtype, severity and outcome. Additionally, the stroke severity of patients with atherosclerotic and cardioembolic stroke was higher than that of patients with TIA, who had low stroke severity. In terms of the NIHSS classification, OPG levels were NS, not statistically significant (P > 0.01). Serum OPG and S-100 protein in acute ischaemic stroke significantly higher in patients with high severity stroke compared with patients with low or moderately severe stroke. OPG levels were also significantly higher in patients who died compared with those who survived. Some authors claim that elevated OPG levels in atherosclerosis are a result of a compensatory defence mechanism to prevent the progression of atherosclerosis. 7, 19 For this reason, the high OPG levels found in patients with atherosclerotic and cardioembolic stroke may be because of the repair of plaque instability. In this respect, it is still unclear whether or not OPG is helpful to the vascular system. The high levels of serum S-100 protein observed in patients with acute stroke in the present study were consistent with other studies in the literature. 20, 21 In studies conducted on large groups of patients, the usefulness of serum S-100 protein has been confirmed. 20, 22 Kim et al. 23 found high S-100 protein levels in 11 patients who had an ischaemic or haemorrhagic stroke. They reported that S-100 protein levels peaked in patients with large ischaemic stroke on the third day, and in patients with haemorrhagic stroke on the first day. Martens et al. 24 evaluated the S-100 protein concentration as a marker for the return to consciousness after brain ischaemia and reported 0.7 ng/ml to be the critical level. Herrmann et al. 21 found that serum S-100 protein levels after a stroke increased in correlation with the size of the brain lesion and neurological status at discharge. In a study of S-100 protein levels in the acute period in patients with stroke, there was a correlation between serum S-100 protein levels, infarct size and short-term clinical prognosis. 25 It was also reported that a single measurement of S-100B protein in the first 12 -24 h after the occurrence of the symptoms is quite valuable in predicting malign middle cerebral artery infarct development, 26 indicating clinical progress and guiding treatment decisions regarding this life-threatening stroke type. Rainer et al. 27 showed that the S-100 protein level increased in 64% of patients in the first 24-h period following a stroke. Serum S-100 protein levels in the present study were higher among patients with atherothrombotic and cardioembolic stroke during the acute period. They were also higher in patients with high severity stroke compared with patients with low severity stroke, and were also higher in patients who died than in survivors. Furthermore, serum S-100 protein level was an independent predictor of mortality.
In conclusion, serum OPG and S-100 protein levels rise in patients with acute ischaemic stroke. Both OPG and S-100 protein levels are predictors in the determination of stroke subtype and severity, but S-100 protein levels are more valuable for predicting mortality. Thus, S-100 protein levels that are measured in the acute period may be a predictor with regard to the direct outcome of a cerebral infarct.
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